INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced a registered direct offering of 3,000,000 shares of common stock priced at $6.30 per share. The offering, expected to close around June 30, 2025, aims to raise approximately $19 million in gross proceeds.
The offering is priced at-the-market under Nasdaq rules, with A.G.P./Alliance Global Partners serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is being made through an effective shelf registration statement previously filed with the SEC.
INmune Bio (NASDAQ: INMB), un'azienda in fase clinica specializzata in infiammazione e immunologia, ha annunciato un'offerta diretta registrata di 3.000.000 azioni ordinarie al prezzo di 6,30 $ per azione. L'offerta, che si prevede si concluda intorno al 30 giugno 2025, mira a raccogliere circa 19 milioni di dollari di proventi lordi.
L'offerta è quotata al prezzo di mercato secondo le regole del Nasdaq, con A.G.P./Alliance Global Partners come unico agente di collocamento. La società intende utilizzare i proventi netti per il capitale circolante e scopi aziendali generali. L'offerta viene effettuata tramite una dichiarazione di registrazione a scaffale efficace precedentemente depositata presso la SEC.
INmune Bio (NASDAQ: INMB), una empresa en etapa clínica especializada en inflamación e inmunología, ha anunciado una oferta directa registrada de 3,000,000 acciones comunes a un precio de $6.30 por acción. La oferta, que se espera cierre alrededor del 30 de junio de 2025, tiene como objetivo recaudar aproximadamente $19 millones en ingresos brutos.
La oferta se realiza al precio de mercado según las reglas de Nasdaq, con A.G.P./Alliance Global Partners como único agente colocador. La empresa planea usar los ingresos netos para capital de trabajo y fines corporativos generales. La oferta se está realizando mediante una declaración de registro en estantería efectiva previamente presentada ante la SEC.
INmune Bio (NASDAQ: INMB)는 임상 단계의 염증 및 면역학 회사로서, 3,000,000주의 보통주를 주당 $6.30에 등록 직접 공모한다고 발표했습니다. 이 공모는 2025년 6월 30일경 종료될 예정이며, 약 1,900만 달러의 총 수익을 목표로 합니다.
이번 공모는 나스닥 규정에 따라 시장 가격으로 책정되었으며, A.G.P./Alliance Global Partners가 단독 배정 대행사로 참여합니다. 회사는 순수익을 운전자본 및 일반 기업 목적에 사용할 계획입니다. 이 공모는 이전에 SEC에 제출된 유효한 선반 등록 명세서를 통해 진행됩니다.
INmune Bio (NASDAQ : INMB), une société en phase clinique spécialisée dans l'inflammation et l'immunologie, a annoncé une offre directe enregistrée de 3 000 000 d'actions ordinaires au prix de 6,30 $ par action. L'offre, dont la clôture est prévue aux alentours du 30 juin 2025, vise à lever environ 19 millions de dollars de produit brut.
L'offre est proposée au prix du marché selon les règles du Nasdaq, avec A.G.P./Alliance Global Partners en tant qu'agent unique de placement. La société prévoit d'utiliser les produits nets pour le fonds de roulement et des fins générales d'entreprise. L'offre est réalisée via une déclaration d'enregistrement sur étagère efficace déposée précédemment auprès de la SEC.
INmune Bio (NASDAQ: INMB), ein klinisch tätiges Unternehmen im Bereich Entzündungen und Immunologie, hat ein registriertes Direktangebot von 3.000.000 Stammaktien zu einem Preis von 6,30 $ pro Aktie angekündigt. Das Angebot, das voraussichtlich um den 30. Juni 2025 abgeschlossen wird, soll etwa 19 Millionen US-Dollar Bruttoerlös einbringen.
Das Angebot wird zum Marktpreis gemäß den Nasdaq-Regeln durchgeführt, wobei A.G.P./Alliance Global Partners als alleiniger Platzierungsagent fungiert. Das Unternehmen plant, die Nettoerlöse für das Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Das Angebot erfolgt über eine zuvor bei der SEC eingereichte wirksame Shelf-Registrierungserklärung.
- Raising approximately $19 million to strengthen working capital position
- Strategic investment from two healthcare-focused institutional investors showing confidence in the company
- Potential dilution for existing shareholders with 3,000,000 new shares being issued
Insights
INmune Bio raises $19M through share offering at $6.30, strengthening its balance sheet for continued clinical operations.
INmune Bio's
The fact that two healthcare-focused institutional investors are participating suggests a level of validation for INmune's inflammation and immunology platform. These specialized investors typically conduct thorough due diligence before committing capital, which can be interpreted as a vote of confidence in the company's scientific approach and management team.
The company's statement that proceeds will be used for "working capital purposes and general corporate procedures" is typical biotech language for extending operational runway. As a clinical-stage company without commercial products, INmune burns cash to fund its R&D and clinical programs. This infusion likely extends their operational timeline by 12-18 months based on typical burn rates for similar-sized clinical biotech companies.
A.G.P./Alliance Global Partners serving as the sole placement agent is notable, as they specialize in healthcare and biotech financings. The use of a registered direct offering rather than a traditional public offering allows for a more streamlined process with potentially lower fees, though it limits the investor base to pre-identified institutions.
Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of
The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately
A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.
The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 279036) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ
What is the size and price of INmune Bio's (INMB) June 2025 stock offering?
When will INmune Bio's (INMB) registered direct offering close?
Who are the investors in INmune Bio's (INMB) June 2025 offering?
How will INmune Bio (INMB) use the proceeds from the offering?
Who is the placement agent for INmune Bio's (INMB) offering?
